Recently, the Ministry of Industry and Information Technology (MIIT) announced the list of the 6th batch of "National Specialized, Refined, Featured, and Innovative 'Little Giant' Enterprises," and AccuMedical Beijing Ltd. was included.
"Specialized, Refined, Featured, and Innovative" is a concept proposed by the MIIT in the 12th Five-Year Plan for Small and Medium Enterprises, and the "Little Giant" enterprises are its leaders. These enterprises focus on niche markets, possess strong innovation capabilities, have a high market share, control key technologies, and deliver excellent quality and efficiency.
AccuMedical, with years of dedication in the field of neurointervention, has developed a comprehensive product line covering both hemorrhagic and ischemic stroke treatment products as well as access assistance devices. The company's self-developed core product, the Lattice® Flow Diverter, has expanded the indications of flow diverters to treat small[S1] and medium-sized vertebral artery aneurysms, filling a critical clinical gap.
Compared to large enterprises, specialized and innovative "Little Giant" enterprises may be smaller in size, but they are "small yet sharp" and "small yet specialized," focusing on specific niche areas for the long term. The field of neurointervention, where AccuMedical specializes, is globally recognized as one with high research difficulty, high technical barriers, high clinical value, and large market potential.
Currently, cerebrovascular diseases have become one of the leading health threats to middle-aged and elderly individuals, with high disability and mortality rates. Statistics show that approximately 1.5 million people die from cerebrovascular diseases in China every year, with intracranial aneurysms, often referred to as "time bombs," posing an ever-present risk of rupture and causing intracranial hemorrhage. The treatment of complex intracranial aneurysms presents challenges such as high surgical difficulty, high complication rates, and high recurrence rates.
Compared to traditional treatments, the Lattice® Flow Diverter developed by AccuMedical is delivered via an interventional approach to the aneurysm-carrying artery. It isolates the aneurysm from the patent artery, redirecting blood flow away from the aneurysm, accelerating thrombosis within the aneurysm, and promoting endothelialization at the aneurysm neck, ultimately repairing the parent artery.
The innovation of Lattice lies in its mechanical balloon delivery system, which actively expands the stent from within, ensuring precise deployment at the treatment site and allowing stent retrieval when necessary. This technology successfully reduces surgical complexity and recovery time, marking a new "automation era" in intracranial aneurysm treatment.
Currently, Lattice is used in hundreds of hospitals across China, demonstrating exceptional clinical performance. Data shows a 91.4% aneurysm occlusion success rate and only a 0.8% in-stent restenosis rate at 12 months post-surgery. Its clinical application has notably reduced surgical complexity, shortened operation time, and improved patient outcomes.
Innovation is the soul of "Specialized, Refined, Featured, and Innovative" enterprises. Only by firmly mastering the core industrial processes and key technologies can small and medium-sized enterprises unleash their tremendous potential. Currently, AccuMedical has applied for more than 118 patents, with 64 granted. These technological achievements provide a solid foundation for AccuMedical’s ongoing innovation and growth in the field of neurointervention.
Previously, AccuMedical's innovation capabilities, strong technological accumulation, and clinical application results of its products have been widely recognized. The Lattice® Flow Diverter has been classified by the National Medical Products Administration (NMPA) as an "Innovative Medical Device" and has been fast-tracked through the "Green Channel" for approval. Additionally, in 2022, AccuMedical was recognized as a "Specialized, Refined, Featured, and Innovative" enterprise by Beijing, and in 2023, it was awarded the title of "National High-Tech Enterprise" and recognized by six departments, including the Beijing Science and Technology Commission, Development and Reform Commission, and Economic and Information Technology Bureau, as a new technology and product enterprise.
Being selected as a "National Specialized, Refined, Featured, and Innovative 'Little Giant' Enterprise" is further affirmation of AccuMedical's investment in research and development and technological innovation. Moving forward, the company will continue to deepen its focus in the neurointervention field, leading with technological innovation, and providing better products and services to global patients and doctors, striving to drive the new development of China's medical device industry.